Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL812654 | 0.84 | PGR (0.50) | PGRTDP2 | |
| SCHEMBL6211150 | 0.83 | PGR (0.52) | PGRTDP2 | |
| SCHEMBL8555344 | 0.77 | CACNB4 (0.38) | PGRGAATP53 | |
| SCHEMBL7142077 | 0.76 | GRIN2D (0.35) | PGRMEN1KMT2AALDH1A1 | |
| SCHEMBL5231465 | 0.76 | SLC9A1 (0.41) | MEN1GAAKMT2ATP53 | |
| SCHEMBL5234343 | 0.72 | CES1 (0.34) | GAA | |
| SCHEMBL11025445 | 0.70 | ACACB (0.38) | PGRGAATDP2TP53ALDH1A1 | |
| SCHEMBL11030508 | 0.68 | DDB1 (0.44) | GAAALDH1A1 | |
| SCHEMBL6589363 | 0.68 | AR (0.37) | PGRKMT2A | |
| SCHEMBL7098243 | 0.66 | ESR2 (0.35) | MEN1GAAKMT2AESR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030096806-A1 | Arylphenyl-substituted cyclic ketoenols | LIEB FOLKER (DE) | 2003-05-22 | — | — | US | disclosed |
| US-6451843-B1 | Arylphenyl-substituted cyclic keto enols | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-17 | — | — | US | disclosed |
| EP-1075465-A1 | ARYLPHENYL-SUBSTITUTED CYCLIC KETO ENOLS | BAYER AG (DE) | 2001-02-14 | — | — | EP | disclosed |
| WO-1999055673-A1 | ARYLPHENYL-SUBSTITUTED CYCLIC KETO ENOLS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096806-A1 | Arylphenyl-substituted cyclic ketoenols | KCNE1, KCNQ3, SULT1E1 | PGR 999/4885MEN1 4817/4885GAA 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.